8-K 1 remedentform8k2.htm FORM 8-K ANNOUNCING FILING OF FORM 15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

~~Form~~FORM 8-K

~~Current~~CURRENT ~~Report Pursuant to Section 13 or 15(d) of~~REPORT

~~The~~Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~ 14June 23, ~~2013~~2021

REMEDENT, INC. (Exact name of registrant as specified in its charter)

~~(Exact~~Commission ~~name~~file ~~of registrant as specified in its charter)~~number 001-15975

Nevada	~~001-15975~~	86-0837251
(State or other jurisdiction	(Commission	(I.R.S. Employer
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification No.)
of incorporation)	File Number)	Identification No.)
Zuiderlaan 1-3 bus 8, 9000 Ghent, Belgium		N/A
(Address of principal executive offices)		(Zip Code)

~~Zuiderlaan 1-3~~Registrant’s ~~bus~~telephone 8number, ~~9000,~~including ~~Ghent,~~area ~~Belgium~~code:011 ~~n/a~~ 32 9 241 58 80

~~(Address of principal executive offices) (Zip Code)~~_____________________________________________

(~~Registrant's~~Former ~~telephone~~name ~~number~~or former address, ~~including~~if ~~area~~changed ~~code:~~since ~~011-329-241-58~~last 80report)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o ____ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o ____ Soliciting material pursuant to Rule 4a14a-12 under the Exchange Act (17 CFR 240.14a-12)

o ____ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 40240.14d-2(b))

o ____ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1Item 8.01 Other Events

~~SECTION~~On 4June 23, 2021, the Company filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended. ~~MATTERS~~ ~~RELATED~~The TOCompany ~~ACCOUNTANTS AND~~is ~~FINANCIAL~~eligible ~~STATEMENTS~~to deregister its common stock by filing a Form 15 under Section 12(g) of the Exchange Act because the Company has fewer than 300 holders of record. The Company’s obligation to file periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, under Section 13(a) of the Exchange Act were suspended upon filing the Form 15. The deregistration under Section 12(g) of the Exchange Act is expected to be effective 90 days after filing the Form 15 at which time the Company’s other filing requirements under Section 13(a) of the Exchange Act will terminate.

~~Item 4.01 Changes in Registrant’s Certifying Accountant.~~1

~~(a) On July~~The ~~25,~~decision ~~2013,~~of the Company’s Board of Directors to deregister its common stock was based on the consideration of ~~Remedent~~numerous ~~Inc.~~factors, (including the "substantial cost savings to the Company") ~~received~~as ~~written~~a ~~notice~~result of ~~Grant~~the ~~Thornton~~elimination ~~Bedrijfsrevisoren CVBA’s~~of ~~decision~~SEC ~~not~~reporting requirements, including the costs relating to ~~stand~~preparing ~~for~~and ~~reappointment~~filing asperiodic ~~the~~reports ~~Company's~~and ~~independent~~other ~~accountants~~SEC documents, legal and accounting costs, compliance costs and other public reporting company-related.

~~Grant~~Item ~~Thornton Bedrijfsrevisoren CVBA's report on the Company's consolidated financial statements for the fiscal year ended March 31, 2013 did not contain an adverse opinion or disclaimer of opinion~~9.01 AFinancial ~~matter~~Statements of emphasis on the uncertainty with regard to going concern has been included in the report. The opinion was not modified with respect to this matter., neither with respect to other uncertainties, audit scope or accounting principles. Grant Thornton Bedrijfsrevisoren CVBA's report on the Company's consolidated financial statements for the fiscal year ended March 31, 2013 and March 31, 2012 did not contain an adverse opinion or disclaimer of opinion. . A matter of emphasis on the uncertainty with regard to going concern has been included in these reports. The opinion was not modified with respect to this matter., neither with respect to other uncertainties, audit scope or accounting principles.Exhibits

~~During~~(d) the years ended March 31, 2005 through July 25, 2013, there were no disagreements with Grant Thornton Bedrijfsrevisoren CVBA on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to Grant Thornton Bedrijfsrevisoren CVBA's satisfaction, would have caused them to make reference to the subject matter of such disagreements in connection with their report on the Company's consolidated financial statements for such years.Exhibits

The Company has provided Grant Thornton Bedrijfsrevisoren CVBA with a copy of the foregoing disclosures. Attached as Exhibit 1.1 is a copy of Grant Thornton Bedrijfsrevisoren CVBA's letter stating there has been no disagreements.

Exhibit Number	Description

99.1	Press release dated June 29, 2021

(b) On October 7, 2013, the Company engaged Vandelanotte Bedrijfsrevisoren CVBA, Brussels, Belgium (“Vandelanotte”) as the company’s new independent accountants to audit the Company’s financial statements for the fiscal year ending March 31, 2014. The decision to change the Company’s independent accountants to Vandelanotte was considered and approved by the Company’s Board of Directors. Neither the Company, nor anyone acting on the Company’s behalf, consulted Vandelanotte regarding any matters specified in Items 304(a)(2)(i) or 304(a)(2)(ii) of Regulation S-B.SIGNATURES

2Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

	REMEDENT, INC.
	(Registrant)

Dated: June 29, 2021	By:	/s/ Guy De Vreese
	Name:	Guy De Vreese
	Title:	Chief Executive Officer

~~(c) Exhibits~~2

Exhibit Description

1.1 Letter from Grant Thornton Bedrijfsrevisoren CVBA.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 14, 2013	/s/ PHILIPPE VAN ACKER
	Philippe Van Acker,
	Chief Financial Officer

Filing Compare · REMEDENT, INC.